Recently, IPMG joined a meeting between the Head of BADAN PENGAWAS OBAT DAN MAKANAN, Prof. dr.?Taruna Ikrar, M.Biomed., Ph.D and Japan Pharmaceutical Manufacturers Association (JPMA), where we witnessed his passion and determination to elevate Badan POM to WHO Listed Authority (WLA) status. This ambitious vision has been a consistent focus for Prof. Ikrar, who reiterated his commitment during the meeting and warmly invited JPMA to share ideas or initiatives to support BPOM in achieving this goal within the next year.
According to the World Health Organization, a WHO Listed Authority (WLA) is a regulatory authority (RA) or a regional regulatory system (RRS) that complies with all the relevant indicators and requirements specified by WHO for regulatory capability as defined by an established benchmarking and performance evaluation process. The WLA framework aims to ensure access to safe, effective, and high-quality medical products while optimizing resources by relying on the outputs of trusted regulatory agencies. This initiative also promotes regulatory convergence, harmonization, and international collaboration, enhancing global regulatory practices.
In response, JPMA expressed its openness to collaborate more frequently to explore opportunities for support and partnership. During this meeting JPMA also introduced the upcoming 14th Asia Partnership Conference of Pharmaceutical Associations (APAC) and invited Badan POM to speak at this event on April 22, 2025.
